Merck
-
Merck expands HIV portfolio with FDA approval of Idvynso single-tablet regimen
The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
European Commission approves Merck’s Enflonsia for RSV prevention in infants
The approval grants the pharmaceutical giant the right to market Enflonsia across all 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.
-
Merck restructures China vaccine deal as Gardasil demand collapses
This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.
-
MSD acquires Cidara Therapeutics for USD9.2B to strengthen influenza prevention pipeline
The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.